Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma

BackgroundLarge-cell neuroendocrine lung carcinoma (LCNEC) is a rare pulmonary neoplasm with poor prognosis and limited therapeutic options.MethodsWe retrospectively analyzed all patients with metastatic LCNEC in the records of a large German academic center since 2010.Results191 patients were ident...

Full description

Bibliographic Details
Main Authors:	David Fisch, Farastuk Bozorgmehr, Daniel Kazdal, Jonas Kuon, Laura V. Klotz, Rajiv Shah, Florian Eichhorn, Mark Kriegsmann, Marc A. Schneider, Thomas Muley, Albrecht Stenzinger, Helge Bischoff, Petros Christopoulos
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-07-01
Series:	Frontiers in Oncology
Subjects:	large-cell neuroendocrine lung carcinoma immunotherapy platinum chemotherapy local therapies overall survival de novo metastatic
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.673901/full

Similar Items

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
by: Farastuk Bozorgmehr, et al.
Published: (2021-04-01)

Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
by: Florian Eichhorn, et al.
Published: (2021-04-01)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
by: Miriam Blasi, et al.
Published: (2021-03-01)

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis
by: Miriam Blasi, et al.
Published: (2022-06-01)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
by: Petros Christopoulos, et al.
Published: (2021-06-01)

Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial
by: Jonas Kuon, et al.
Published: (2020-04-01)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
by: Stephan Rheinheimer, et al.
Published: (2020-04-01)

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
by: Mark Kriegsmann, et al.
Published: (2020-09-01)

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer
by: Mark Kriegsmann, et al.
Published: (2020-06-01)

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
by: Farastuk Bozorgmehr, et al.
Published: (2023-08-01)

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
by: Farastuk Bozorgmehr, et al.
Published: (2020-08-01)

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
by: Hannah Schindler, et al.
Published: (2022-10-01)

Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition
by: Philip Baum, et al.
Published: (2021-04-01)

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib
by: Julia Kunz, et al.
Published: (2022-05-01)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat
by: Nicolas Hohmann, et al.
Published: (2021-03-01)

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial
by: Farastuk Bozorgmehr, et al.
Published: (2022-09-01)

Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
by: Eva Romanovsky, et al.
Published: (2023-04-01)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
by: Steffen Dietz, et al.
Published: (2020-12-01)

Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading
by: Moritz Jesinghaus, et al.
Published: (2022-11-01)

Automated sample preparation with SP3 for low‐input clinical proteomics
by: Torsten Müller, et al.
Published: (2020-01-01)

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial
by: Farastuk Bozorgmehr, et al.
Published: (2019-11-01)

Corrigendum: Deep learning for the detection of anatomical tissue structures and neoplasms of the skin on scanned histopathological tissue sections
by: Katharina Kriegsmann, et al.
Published: (2023-05-01)

Deep learning for the detection of anatomical tissue structures and neoplasms of the skin on scanned histopathological tissue sections
by: Katharina Kriegsmann, et al.
Published: (2022-11-01)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
by: Tanja Eichkorn, et al.
Published: (2020-12-01)

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
by: Arlou Kristina Angeles, et al.
Published: (2021-12-01)

Lung Adenocarcinoma Diagnosed at a Younger Age Is Associated with Advanced Stage, Female Sex, and Ever-Smoker Status, in Patients Treated with Lung Resection
by: Tommaso A. Dragani, et al.
Published: (2023-04-01)

Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages
by: Florian Janke, et al.
Published: (2020-04-01)

Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
by: Michael Menzel, et al.
Published: (2024-03-01)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
by: Petros Christopoulos, et al.
Published: (2019-01-01)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
by: Sarah Richtmann, et al.
Published: (2019-05-01)

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
by: Jan Budczies, et al.
Published: (2018-12-01)

Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy
by: Christoph A. Fink, et al.
Published: (2023-09-01)

High-risk patients with locally advanced non-small cell lung cancer treated with stereotactic body radiation therapy to the peripheral primary combined with conventionally fractionated volumetric arc therapy to the mediastinal lymph nodes
by: Tanja Eichkorn, et al.
Published: (2023-01-01)

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
by: Jan Budczies, et al.
Published: (2022-07-01)

Current Management and Future Perspective in Pleural Mesothelioma
by: Rajiv Shah, et al.
Published: (2022-02-01)

Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation
by: Petros Christopoulos, et al.
Published: (2023-04-01)

Epigenetic Inactivation of the Tumor Suppressor <i>IRX1</i> Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis
by: Miriam M. Küster, et al.
Published: (2020-11-01)

Biological injection therapy with leukocyte-poor platelet-rich plasma induces cellular alterations, enhancement of lubricin, and inflammatory downregulation in vivo in human knees: A controlled, prospective human clinical trial based on mass spectrometry imaging analysis
by: Axel W. Baltzer, et al.
Published: (2023-04-01)

Identification of Gastritis Subtypes by Convolutional Neuronal Networks on Histological Images of Antrum and Corpus Biopsies
by: Georg Steinbuss, et al.
Published: (2020-09-01)

Are statins worthy for treatment of periodontitis? A systematic review and meta-analysis
by: Monali Shah, et al.
Published: (2017-01-01)